

# EULAR 2024 Congress

June 12–15, 2024  
Vienna, Austria



## TOP ABSTRACTS

To help navigate the exciting content being presented at European Alliance of Associations for Rheumatology (EULAR) Congress (EULAR 2024), we have provided recommendations for the top abstracts to look out for in psoriasis and psoriatic arthritis.

# EULAR 2024: Top abstracts in psoriasis and psoriatic arthritis

June 12–15, 2024

Psoriasis	
Abstract	Title
<b>POS0988</b> <a href="#">View</a>	What is the role of biologics in preventing arthritis in patients with psoriasis? A retrospective study
<b>POS0942</b> <a href="#">View</a>	VISIBLE: Clearance and symptom improvement with guselkumab at Week 16 in skin of color participants with moderate-to-severe plaque psoriasis
<b>OP00010</b> <a href="#">View</a>	Evaluation of the risk of psoriatic arthritis in patients with psoriasis undergoing biological treatment. Global population study (TRINETX) <b><u>Wednesday, June 12, 16:40 –16:50</u></b>

Psoriatic arthritis	
Abstract	Title
<b>OP0138</b> <a href="#">View</a>	Efficacy and safety outcomes of TAK-279, a selective oral tyrosine kinase 2 (TYK2) inhibitor, from a randomized, double-blind, placebo-controlled phase 2b trial in patients with active psoriatic arthritis <b><u>Thursday, June 13, 10:50 –11:00</u></b>
<b>OP0195</b> <a href="#">View</a>	Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody®, in patients with active psoriatic arthritis (PsA): Results from the global, randomized, double-blind, placebo-controlled Phase 2 ARGO trial <b><u>Thursday, June 13, 11:40 –11:50</u></b>
<b>POS0943</b> <a href="#">View</a>	Guselkumab provides durable improvements in pain among patients with psoriatic arthritis and an inadequate response to TNFi: COSMOS Phase 3b trial
<b>POS0945</b> <a href="#">View</a>	Sustainability of response with upadacitinib in patients with moderately to severely active psoriatic arthritis: Week 152 data from the SELECT-PsA 1 and SELECT-PsA 2 trials
<b>POS0968</b> <a href="#">View</a>	Apremilast reduces inflammation as measured by MRI, clinical outcomes, and patient-reported outcomes in patients with psoriatic arthritis: Results from the Phase 4 MOSAIC study
<b>POS0969</b> <a href="#">View</a>	Bimekizumab-treated patients with active psoriatic arthritis showed sustained achievement of minimal disease activity and remission: Up to 2-year results from two Phase 3 studies
<b>POS0992</b> <a href="#">View</a>	PARIS study: Potential biomarkers predicting response to TNFi in psoriatic arthritis



## EULAR 2024

Follow us on X to keep up to date  
with the latest from the congress

**@psoriasis\_hub**

**#EULAR2024**

**View all @psoriasis\_hub tweets from #EULAR2024**



# PsOPsAHub

Brought to you by

